Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial

Trastuzumab is a remarkably effective therapy for patients with human epidermal growth factor receptor 2 (HER2) - positive breast cancer (BC). However, not all women with high levels of HER2 benefit from trastuzumab. By integrating mRNA and protein expression data from Reverse-Phase Protein Array An...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonnenblick, Amir, Brohée, Sylvain, Fumagalli, Debora, Rothé, Françoise, Vincent, Delphine, Ignatiadis, Michael, Desmedt, Christine, Salgado, Roberto, Sirtaine, Nicolas, Loi, Sherene, Neven, Patrick, Loibl, Sibylle, Denkert, Carsten, Joensuu, Heikki, Piccart, Martine, Sotiriou, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745800/
https://www.ncbi.nlm.nih.gov/pubmed/26358523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745800/
https://www.ncbi.nlm.nih.gov/pubmed/26358523

Ejemplares similares